Update: current management issues in malignant melanoma
| Autor: | John M. Kirkwood, Andrea Rocca, Mirko Acquati, Alessandro Testori, Alexander M.M. Eggermont, Paola Queirolo |
|---|---|
| Přispěvatelé: | Surgery |
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy business.industry Incidence (epidemiology) Melanoma medicine.medical_treatment Dermatology medicine.disease Nitrosourea Compounds Organophosphorus Compounds Current management Chemotherapy Adjuvant Internal medicine Adjuvant therapy Humans Medicine Fotemustine Relapse risk business Standard therapy medicine.drug |
| Zdroj: | Melanoma Research, 15(5), 319-324. Lippincott Williams & Wilkins |
| ISSN: | 1473-5636 0960-8931 |
| DOI: | 10.1097/00008390-200510000-00001 |
| Popis: | The incidence of melanoma has increased continuously during the last decade. Surgery is the mainstay of therapy but, for patients with thick lesions or regional metastatic lymph nodes, there is a high risk of relapse. For this group of patients, there is no standard therapy or general agreement amongst oncologists. In this article, we review the current management of melanoma with regard to past completed adjuvant trials and open trials. Moreover, we discuss the role of chemotherapy in metastatic melanoma, in particular with attention to the use of fotemustine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|